Manulife (Manufacturers Life Insurance)
TRVI icon

Manulife (Manufacturers Life Insurance)’s Trevi Therapeutics TRVI Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$925K Buy
49,611
+6,050
+14% +$88K ﹤0.01% 1997
2026
Q1 		$520K Buy
43,561
+15,624
+56% +$175K ﹤0.01% 2140
2025
Q4 		$350K Sell
27,937
-1,678
-6% -$19.4K ﹤0.01% 2310
2025
Q3 		$271K Buy
29,615
+1,296
+5% +$9.72K ﹤0.01% 2430
2025
Q2 		$155K Buy
28,319
+3,907
+16% +$24.3K ﹤0.01% 2645
2025
Q1 		$154K Buy
24,412
+981
+4% +$4.68K ﹤0.01% 2577
2024
Q4 		$96.5K Sell
23,431
-711
-3% -$2.28K ﹤0.01% 2823
2024
Q3 		$80.6K Sell
24,142
-382
-2% -$1.14K ﹤0.01% 2914
2024
Q2 		$73.1K Buy
24,524
+11,450
+88% +$31.8K ﹤0.01% 2905
2024
Q1 		$45.1K Buy
+13,074
New +$29.2K ﹤0.01% 2894

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s TRVI Position: Q2 2026 in Review

Manulife (Manufacturers Life Insurance) increased its Trevi Therapeutics (TRVI) stake by 14% in Q2 2026, buying an estimated $88K and bringing the position to 49,611 shares worth $925K. The position accounts for ﹤0.01% of the portfolio, ranked #1997.

Manulife (Manufacturers Life Insurance) first reported a position in TRVI in Q1 2024 and has held it in 10 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Manulife (Manufacturers Life Insurance) held 49,611 shares of Trevi Therapeutics worth $925K as of Q2 2026.
  • Manulife (Manufacturers Life Insurance) bought 6,050 Trevi Therapeutics shares in Q2 2026, an estimated $88K.
  • Trevi Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q2 2026, its #1997 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Trevi Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2026, filed 14 Aug 2026.